Mutual of America Capital Management LLC Raises Stock Holdings in IDEXX Laboratories, Inc. $IDXX

Mutual of America Capital Management LLC boosted its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 1.1% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 19,642 shares of the company’s stock after buying an additional 212 shares during the period. Mutual of America Capital Management LLC’s holdings in IDEXX Laboratories were worth $10,535,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the company. William Blair Investment Management LLC grew its position in IDEXX Laboratories by 7.5% in the 2nd quarter. William Blair Investment Management LLC now owns 685,088 shares of the company’s stock valued at $367,440,000 after acquiring an additional 47,977 shares in the last quarter. Quotient Wealth Partners LLC acquired a new position in IDEXX Laboratories in the 2nd quarter valued at about $212,000. Stratos Wealth Partners LTD. grew its position in IDEXX Laboratories by 1.7% in the 2nd quarter. Stratos Wealth Partners LTD. now owns 1,051 shares of the company’s stock valued at $564,000 after acquiring an additional 18 shares in the last quarter. Nordea Investment Management AB grew its position in IDEXX Laboratories by 4.7% in the 2nd quarter. Nordea Investment Management AB now owns 8,057 shares of the company’s stock valued at $4,298,000 after acquiring an additional 361 shares in the last quarter. Finally, Aware Super Pty Ltd as trustee of Aware Super grew its position in IDEXX Laboratories by 41.8% in the 2nd quarter. Aware Super Pty Ltd as trustee of Aware Super now owns 62,291 shares of the company’s stock valued at $33,409,000 after acquiring an additional 18,375 shares in the last quarter. 87.84% of the stock is owned by institutional investors and hedge funds.

IDEXX Laboratories Price Performance

IDXX stock opened at $635.40 on Monday. The business has a 50 day moving average price of $639.99 and a 200 day moving average price of $551.18. The stock has a market cap of $50.83 billion, a price-to-earnings ratio of 52.91, a PEG ratio of 4.11 and a beta of 1.58. IDEXX Laboratories, Inc. has a fifty-two week low of $356.14 and a fifty-two week high of $688.12. The company has a quick ratio of 0.79, a current ratio of 1.11 and a debt-to-equity ratio of 0.31.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Monday, August 4th. The company reported $3.63 earnings per share for the quarter, topping the consensus estimate of $3.28 by $0.35. The firm had revenue of $1.11 billion during the quarter, compared to analysts’ expectations of $1.06 billion. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The firm’s revenue was up 10.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.44 earnings per share. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. Equities research analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Insider Activity

In related news, EVP Michael Lane sold 8,411 shares of the business’s stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $627.74, for a total transaction of $5,279,921.14. Following the completion of the sale, the executive vice president owned 7,132 shares in the company, valued at $4,477,041.68. The trade was a 54.11% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Nimrata Hunt sold 1,200 shares of the business’s stock in a transaction that occurred on Monday, August 11th. The stock was sold at an average price of $656.53, for a total value of $787,836.00. Following the sale, the executive vice president owned 16,807 shares of the company’s stock, valued at approximately $11,034,299.71. The trade was a 6.66% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 54,057 shares of company stock valued at $34,293,468 over the last 90 days. Insiders own 0.98% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Stifel Nicolaus set a $640.00 target price on IDEXX Laboratories in a research report on Monday, August 4th. Morgan Stanley lifted their target price on IDEXX Laboratories from $722.00 to $765.00 and gave the company an “overweight” rating in a research report on Friday, August 15th. Leerink Partners lifted their target price on IDEXX Laboratories from $580.00 to $600.00 and gave the company an “outperform” rating in a research report on Thursday, July 17th. BTIG Research lifted their target price on IDEXX Laboratories from $545.00 to $785.00 and gave the company a “buy” rating in a research report on Tuesday, August 5th. Finally, Wall Street Zen downgraded IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Sunday, September 28th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $656.50.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.